A clinical trial into breast cancer research carried out by a Sudbury-based diagnostics company has concluded Phase 1 of its study "with promising results,” said a news release from the Health Sciences North Research Institute .
BREVITY is described as a clinical trial that aims to confirm whether a test called the RNA Disruption Assay can be used to effectively predict the outcome of treatment for patients who are receiving pre-operative chemotherapy, said the release. "With this knowledge, medical teams can quickly determine whether they need to escalate or change course during cancer treatment, with the aim to ultimately improve patient outcomes," said the release.
The research could help patients everywhere, said Dr. Amadeo Parissenti, the chief scientific officer for RNA Diagnostics, and a senior scientist with HSNRI.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SooToday - 🏆 8. / 85 Read more »